NZ703129A - Indolecarbonitriles as selective androgen receptor modulators - Google Patents

Indolecarbonitriles as selective androgen receptor modulators

Info

Publication number
NZ703129A
NZ703129A NZ703129A NZ70312913A NZ703129A NZ 703129 A NZ703129 A NZ 703129A NZ 703129 A NZ703129 A NZ 703129A NZ 70312913 A NZ70312913 A NZ 70312913A NZ 703129 A NZ703129 A NZ 703129A
Authority
NZ
New Zealand
Prior art keywords
indolecarbonitriles
androgen receptor
receptor modulators
selective androgen
compound
Prior art date
Application number
NZ703129A
Other languages
English (en)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703129(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of NZ703129A publication Critical patent/NZ703129A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ703129A 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators NZ703129A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
NZ703129A true NZ703129A (en) 2017-06-30

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703129A NZ703129A (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Country Status (39)

Country Link
US (5) US8957104B2 (instruction)
EP (1) EP2875013B1 (instruction)
JP (1) JP6106746B2 (instruction)
KR (1) KR102127939B1 (instruction)
CN (1) CN104619693B (instruction)
AR (1) AR091770A1 (instruction)
AU (1) AU2013291721B2 (instruction)
BR (1) BR112015000940B1 (instruction)
CA (1) CA2879104C (instruction)
CL (1) CL2015000119A1 (instruction)
CO (1) CO7240378A2 (instruction)
CR (1) CR20150008A (instruction)
CY (1) CY1120064T1 (instruction)
DK (1) DK2875013T3 (instruction)
DO (1) DOP2015000004A (instruction)
EA (1) EA026371B8 (instruction)
ES (1) ES2657912T3 (instruction)
HR (1) HRP20180061T1 (instruction)
HU (1) HUE036238T2 (instruction)
IL (1) IL236448A (instruction)
IN (1) IN2014KN02993A (instruction)
JO (1) JO3384B1 (instruction)
LT (1) LT2875013T (instruction)
ME (1) ME02996B (instruction)
MX (1) MX349943B (instruction)
MY (2) MY198512A (instruction)
NZ (1) NZ703129A (instruction)
PE (1) PE20150371A1 (instruction)
PH (1) PH12015500104A1 (instruction)
PL (1) PL2875013T3 (instruction)
PT (1) PT2875013T (instruction)
RS (1) RS56810B1 (instruction)
SG (1) SG11201408493WA (instruction)
SI (1) SI2875013T1 (instruction)
SM (1) SMT201800115T1 (instruction)
TW (1) TWI574946B (instruction)
UY (1) UY34911A (instruction)
WO (1) WO2014013309A1 (instruction)
ZA (1) ZA201500096B (instruction)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
TWI574946B (zh) 2012-07-17 2017-03-21 葛蘭素史密斯克藍智慧財產權有限公司 化合物
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
WO2016061534A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000552A2 (en) 1998-02-25 2001-04-30 Genetics Inst Inhibitors of phospholipase enzymes
BR9911365A (pt) * 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
WO2003099777A1 (en) 2002-05-24 2003-12-04 Bayer Cropscience Ag Process for the preparation of thioalkylamine derivatives
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
ES2371170T3 (es) 2004-05-03 2011-12-28 Janssen Pharmaceutica Nv Derivados de benzofurano comomoduladores selectivos de receptores de andrógenos (msra).
WO2005111042A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
CA2564952A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
WO2005118539A1 (en) * 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
CA2614907C (en) * 2005-07-29 2012-02-28 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
AU2007227681A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
WO2008042571A2 (en) * 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
JP4884570B2 (ja) * 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
JP5629324B2 (ja) * 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
WO2012097744A1 (en) * 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
JP6075736B2 (ja) * 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
TWI574946B (zh) * 2012-07-17 2017-03-21 葛蘭素史密斯克藍智慧財產權有限公司 化合物
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
US11299457B2 (en) 2022-04-12
US20190127326A1 (en) 2019-05-02
CR20150008A (es) 2015-03-09
MY173845A (en) 2020-02-24
RS56810B1 (sr) 2018-04-30
PT2875013T (pt) 2018-02-28
DK2875013T3 (en) 2018-01-22
EP2875013A1 (en) 2015-05-27
CY1120064T1 (el) 2018-12-12
SI2875013T1 (en) 2018-03-30
LT2875013T (lt) 2018-02-26
UY34911A (es) 2014-02-28
IL236448A0 (en) 2015-02-26
EA026371B8 (ru) 2017-06-30
DOP2015000004A (es) 2015-03-15
MX349943B (es) 2017-08-21
WO2014013309A1 (en) 2014-01-23
PE20150371A1 (es) 2015-03-27
ES2657912T3 (es) 2018-03-07
PH12015500104B1 (en) 2015-03-02
TW201416349A (zh) 2014-05-01
US9533948B2 (en) 2017-01-03
CA2879104C (en) 2020-08-25
SMT201800115T1 (it) 2018-03-08
US20170073309A1 (en) 2017-03-16
KR102127939B1 (ko) 2020-06-29
EP2875013B1 (en) 2017-11-29
HRP20180061T1 (hr) 2018-02-23
HK1208867A1 (en) 2016-03-18
SG11201408493WA (en) 2015-02-27
US10710963B2 (en) 2020-07-14
MX2015000825A (es) 2015-07-17
US8957104B2 (en) 2015-02-17
ME02996B (me) 2018-10-20
TWI574946B (zh) 2017-03-21
US20150080449A1 (en) 2015-03-19
AU2013291721A1 (en) 2015-02-26
PH12015500104A1 (en) 2015-03-02
CN104619693A (zh) 2015-05-13
CL2015000119A1 (es) 2015-04-24
HUE036238T2 (hu) 2018-06-28
MY198512A (en) 2023-09-01
IN2014KN02993A (instruction) 2015-05-08
PL2875013T3 (pl) 2018-06-29
BR112015000940B1 (pt) 2022-05-17
JP2015522603A (ja) 2015-08-06
EA201492237A1 (ru) 2015-06-30
ZA201500096B (en) 2017-07-26
KR20150032333A (ko) 2015-03-25
CN104619693B (zh) 2019-08-13
CA2879104A1 (en) 2014-01-23
IL236448A (en) 2016-10-31
US20200270210A1 (en) 2020-08-27
US10196353B2 (en) 2019-02-05
AU2013291721B2 (en) 2016-02-25
US20140024694A1 (en) 2014-01-23
JP6106746B2 (ja) 2017-04-05
CO7240378A2 (es) 2015-04-17
JO3384B1 (ar) 2019-03-13
EA026371B1 (ru) 2017-03-31
AR091770A1 (es) 2015-02-25
BR112015000940A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
NZ703129A (en) Indolecarbonitriles as selective androgen receptor modulators
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
WO2015010054A3 (en) Neuroactive steroids, compositions, and uses thereof
IN2014DN09434A (instruction)
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
ZA201508231B (en) Compositions,uses and methods for treatment of metabolic disorders and diseases
PH12015501404B1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2015007916A (es) Peri-carbinoles.
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2013158928A3 (en) Chemosensory receptor ligand-based therapies
PH12014500355A1 (en) Lysophosphatidic acid receptor antagonists
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
MX2016002794A (es) Compuestos antiproliferativos.
MX2014010563A (es) Benzodioxanos en combinacion con otros activos para inhibir la produccion de leucotrieno.
UA113620C2 (xx) Композиція, що містить аморфну (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)оцтову кислоту
PH12014501078A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11�-17-21-triol-3,20-dione derivatives
MY164354A (en) Asymmetric ureas and medical uses thereof
WO2014066799A3 (en) Modulators of resistant androgen receptor
TN2013000283A1 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
MX337612B (es) Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY THOMSON REUTERS

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2020 BY THOMSON REUTERS

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2021 BY THOMSON REUTERS

Effective date: 20200622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2022 BY ANAQUA SERVICES

Effective date: 20210624

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2023 BY ANAQUA SERVICES

Effective date: 20220621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2024 BY ANAQUA SERVICES

Effective date: 20230621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2025 BY ANAQUA SERVICES

Effective date: 20240619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2026 BY ANAQUA SERVICES

Effective date: 20250620